United States
Food and Drug Administration (FDA)
Verified 12 September 2026 by Wilson Blaney, ACQI, RP (GDP) trained
6 days agoMarketing authorisation fees and the governing instrument were re checked against the regulator. Each amount is traceable to the schedule named in its note.
Sources checked
- Federal Register, Prescription Drug User Fee Rates for Fiscal Year 2026 and 2027
- Federal Register, Generic Drug User Fee Rates for Fiscal Year 2026 and 2027
- Federal Register, Biosimilar User Fee Rates for Fiscal Year 2026 and 2027
Contributor Wilson Blaney, ACQI, RP (GDP) trained
The United States is the world's largest pharmaceutical market and operates an independent, non-reliance regulatory system administered by the Food and Drug Administration (FDA). Marketing authorisation is granted under the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act, with new chemical entities reviewed under New Drug Applications (NDA) and biologics under Biologics License Applications (BLA). FDA does not formally rely on foreign regulator decisions but accepts foreign clinical data conducted under ICH-GCP. User fees set under the Prescription Drug User Fee Act (PDUFA VII, FY2023 to 2027) and the Generic Drug User Fee Amendments (GDUFA III, FY2023 to 2027) drive the majority of CDER's review budget and underpin formal review-clock commitments, 10 months for standard NDAs, 6 months for priority review. The post-approval landscape is shaped by the Drug Supply Chain Security Act (DSCSA), in full enforcement since November 2024, which mandates electronic, interoperable, item-level traceability of prescription drugs. The Inflation Reduction Act (2022) introduced direct Medicare price negotiation for selected high-spend drugs, fundamentally changing the US pricing dynamic for branded medicines.
About the authority
The FDA is an agency of the US Department of Health and Human Services. Drug review is conducted by the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER); biological products other than blood, vaccines, allergenics, and cell/gene therapies are reviewed by CDER following the 2003 transfer. The Office of Generic Drugs (within CDER) reviews ANDAs. FDA does not operate a reliance pathway but does accept foreign-generated data and conducts joint inspections under MRAs with the EU, UK, Switzerland, and others.
Reliance & recognition
FDA does not operate a formal reliance pathway. Foreign approval status is not a determinant of FDA review. However, foreign clinical data conducted under ICH-GCP is routinely accepted, and FDA participates in joint reviews under Project Orbis (oncology) and the Access Consortium for selected products. Mutual Recognition Agreements with the EU (since 2017) and UK (since 2024) enable acceptance of GMP inspection outcomes.
Compare United States side-by-side
Benchmark timelines, fees and pathway requirements against another market.
Other Americas markets
Same structure. Same source-citation standard.